Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
Exact Sciences (EXAS) Stock Price & Analysis
2,930 Followers
EXAS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$56.05 - $100.77
Previous Close$60.01
Volume1.59M
Average Volume (3M)2.49M
Market Cap
$11.03B
Enterprise Value$12.81B
Total Cash (Recent Filing)$777.64M
Total Debt (Recent Filing)$2.55B
Price to Earnings (P/E)-52.9
Beta1.80
Next Earnings
May 08, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding181,530,967
10 Day Avg. Volume2,010,701
30 Day Avg. Volume2,494,587
Standard Deviation0.15
R-Squared0.19
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-9.69
Price to Sales (P/S)16.84
Price to Cash Flow (P/CF)38.70
P/FCF Ratio63.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.12
Enterprise Value/Gross Profit6.94
Enterprise Value/Ebitda450.80
Forecast
1Y Price Target
$90.27Price Target Upside49.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Exact Sciences News
PremiumStock Analysis & Ideas
ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy?
PremiumCompany Announcements
Exact Sciences Announces Board Member Retirement
PremiumCompany Announcements
Exact Sciences Appoints Aaron Bloomer as New CFOBulls Say, Bears Say
Bulls Say
Market ExpansionNew markets for Cologuard Plus are being contemplated, potentially unlocking a $6 billion upside pending USPSTF guidelines.
Product PerformanceExact Sciences' Cologuard demonstrates significantly higher sensitivity compared to Freenome's blood test, indicating a competitive advantage.
Revenue GrowthManagement noted that rescreens represented a significant portion of Screening revenue in 2023 and expects the rescreen pool to increase, indicating potential for revenue growth.
Bears Say
Clinical Trials And ReimbursementEXAS is likely to hold back on its large scale SOAR trial until there is more clarity on the reimbursement pathway for MCEDs from Congress.
Financial GuidanceThe Q1 guide came in below consensus with the company expecting a lighter performance in the first quarter.
Product PerformanceFreenome's blood test for CRC screening underperforms with only 79% sensitivity and 12.5% advanced adenoma sensitivity.
---
Ownership Overview
3.23% Insiders
38.31% Mutual Funds
21.91% Other Institutional Investors
36.55% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $56.05 and its highest was $100.77 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Currently, no data Available
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is May 08, 2024 which is tomorrow.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on Feb 21, 2024. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.423 by $0.153.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -$0.48.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 183,850,130 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.423. Following the earnings report the stock price went down -6.004%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Among the largest hedge funds holding Exact Sciences Corp.’s share is ARK Investment Management LLC. It holds Exact Sciences Corp.’s shares valued at 446M.
---
Exact Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.27 (49.11% Upside)
$90.27 (49.11% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 627.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.36%
12-Months-Change
Fundamentals
Return on Equity
-6.60%
Trailing 12-Months
Asset Growth
3.37%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
---
EXAS Company Deck
---
EXAS Earnings Call
Q4 2024
0:00 / 0:00
---
EXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
---
EXAS Stock 12 Months Forecast
Average Price Target
$90.27
▲(49.11% Upside)
Technical Analysis
Best Analysts Covering EXAS
1 Year
1 Year Success Rate
15/20 ratings generated profit
1 Year Average Return
+35.47%
initiated a buy rating 5 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +35.47% per trade.
---